Sharper eye on prostate cancer: new imaging agent could spot recurrence early

NCT ID NCT04186845

Completed Diagnosis Sponsor: Blue Earth Diagnostics Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 study tested a new radioactive imaging agent, rhPSMA-7.3 (18F), in 391 men with suspected prostate cancer recurrence after initial treatment. The agent is used during a PET scan to highlight cancer cells. The goal was to see how well it detects where the cancer has returned. Results could lead to more accurate diagnosis and better salvage therapy planning.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: flotufolastat F18 (rhPSMA-7.3) injection
What this could lead to: If successful, this imaging agent could help doctors more accurately detect where prostate cancer has returned, guiding better treatment decisions.
What could go wrong: This is a diagnostic study, not a treatment. The agent may not detect all recurrences, and false positives are possible. Results need confirmation in broader practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

CWZ

Nijmegen, 6532, Netherlands
Chesapeake Urology Research Associates

Towson, Maryland, 21204, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Duke University Medical Center

Durham, North Carolina, 27701, United States
Emory University Hospital

Atlanta, Georgia, 30322, United States
John Wayne Cancer Institute

Santa Monica, California, 90403, United States
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Loyola University Medical Center

Maywood, Illinois, 60153, United States
MD Anderson Hospital

Houston, Texas, 77054, United States
Maxima MC

Veldhoven, 5504 DB, Netherlands
MidLantic Urology

Philadelphia, Pennsylvania, 19004, United States
Montefiore Hospital

The Bronx, New York, 10461, United States
Mount Sinai Faculty Practice Associates

New York, New York, 10029, United States
Northshore University HealthSystem

Evanston, Illinois, 60201, United States
Northside Hospital

Austell, Georgia, 30342, United States
Queens Hospital Center (QHC - Queens Cancer Center

Jamaica, New York, 11432, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

Baltimore, Maryland, 21287, United States
Stony Brook University

Stony Brook, New York, 11794, United States
Tower Urology

Los Angeles, California, 90048, United States
Turku University Hospital

Turku, FI-20520, Finland
University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35233, United States
University of California Irvine Medical Center (UCIMC)

Orange, California, 92868, United States
University of Michigan Ann Arbor

Ann Arbor, Michigan, 48109, United States
University of Virginia - Health Science Center

Charlottesville, Virginia, 22908, United States
Urology San Antonio

San Antonio, Texas, 78229, United States
Virginia Oncology Associates

Norfolk, Virginia, 23502, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.